18F-FDG positron emission tomography: Potential utility in the assessment of Crohn's disease

Abdominal Imaging

Volumn 37, Issue 3, 2012, Pages 377-386

  Shyn, Paul B ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Computed tomography; Crohn's disease; Positron emission tomography

Indexed keywords

FLUORODEOXYGLUCOSE F 18; DIAGNOSTIC AGENT; RADIOPHARMACEUTICAL AGENT;

ARTICLE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CROHN DISEASE; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; DISEASE ACTIVITY; DISEASE SEVERITY; HUMAN; MONITORING; NON INVASIVE PROCEDURE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; QUANTITATIVE DIAGNOSIS; RELIABILITY; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY; SYMPTOM; METHODOLOGY; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOLOGY; REVIEW; SCINTISCANNING;

CROHN DISEASE; FLUORODEOXYGLUCOSE F18; HUMANS; MAGNETIC RESONANCE IMAGING; POSITRON-EMISSION TOMOGRAPHY; POSITRON-EMISSION TOMOGRAPHY AND COMPUTED TOMOGRAPHY; RADIOPHARMACEUTICALS; SENSITIVITY AND SPECIFICITY;

EID: 84863716123     PISSN: 09428925     EISSN: 14320509     Source Type: Journal    
DOI: 10.1007/s00261-011-9793-y     Document Type: Article

References (50)

1. Abraham C, Cho JH (2009) Inflammatory bowel disease. N Engl J Med 361:2066-2078
2. Loftus EV Jr, Schoenfeld P, Sandborn WJ (2002) The epidemiology and natural history of Crohn's disease in population-based patient cohorts from North America: a systematic review. Aliment Pharmacol Ther 16:51-60
3. Silverstein MD, Loftus EV, Sandborn WJ, et al. (1999) Clinical course and costs of care for Crohn's disease: Markov model analysis of a population-based cohort. Gastroenterology 117:49-57
4. Michelassi F, Balestracci T, Chappell R, Block GE (1991) Primary and recurrent Crohn's disease. Experience with 1379 patients. Ann Surg 214:230-238 (discussion 238-40)
5. Mekhjian HS, Switz DM, Melnyk CS, Rankin GB, Brooks RK (1979) Clinical features and natural history of Crohn's disease. Gastroenterology 77:898-906
6. Rutgeerts P, Geboes K, Vantrappen G, et al. (1990) Predictability of the postoperative course of Crohn's disease. Gastroenterology 99:956-963
7. Van Assche G, Vermeire S, Rutgeerts P (2010) The potential for disease modification in Crohn's disease. Nature reviews. Gastroenterol Hepatol 7:79-85
8. Louis E, Collard A, Oger AF, et al. (2001) Behaviour of Crohn's disease according to the Vienna classification: changing pattern over the course of the disease. Gut 49:777-782
9. Guimaraes LS, Fidler JL, Fletcher JG, et al. (2010) Assessment of appropriateness of indications for CT enterography in younger patients. Inflamm Bowel Dis 16:226-232
10. Rimola J, Rodriguez S, Garcia-Bosch O, et al. (2009) Magnetic resonance for assessment of disease activity and severity in ileocolonic Crohn's disease. Gut 58:1113-1120
11. Lee SS, Kim AY, Yang SK, et al. (2009) Crohn disease of the small bowel: comparison of CT enterography, MR Enterography, and small-bowel follow-through as diagnostic techniques. Radiology 251:751-761
12. Booya F, Fletcher JG, Huprich JE, et al. (2006) Active Crohn disease: CT findings and interobserver agreement for enteric phase CT enterography. Radiology 241:787-795
13. Bodily KD, Fletcher JG, Solem CA, et al. (2006) Crohn disease: mural attenuation and thickness at contrast-enhanced CT Enterography- correlation with endoscopic and histologic findings of inflammation. Radiology 238:505-516
14. Florie J, Wasser MN, Arts-Cieslik K, et al. (2006) Dynamic contrast- enhanced MRI of the bowel wall for assessment of disease activity in Crohn's disease. AJR Am J Roentgenol 186:1384-1392
15. Punwani S, Rodriguez-Justo M, Bainbridge A, et al. (2009) Mural inflammation in Crohn disease: location-matched histologic validation of MR imaging features. Radiology 252:712-720
16. Sempere GA, Sanjuan VM, Chulia EM, et al. (2005) MRI evaluation of inflammatory activity in Crohn's disease. AJR Am J Roentgenol 184:1829-1835
17. D'Haens GR (2010) Top-down therapy for IBD: rationale and requisite evidence. Nature reviews. Gastroenterol Hepatol 7:86-92
18. Cohen RD (2010) The pharmacoeconomics of biologic therapy for IBD. Nature reviews. Gastroenterol Hepatol 7:103-109
19. Kandiel A, Fraser AG, Korelitz BI, Brensinger C, Lewis JD (2005) Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine. Gut 54:1121-1125
20. D'Haens G (2007) Risks and benefits of biologic therapy for inflammatory bowel diseases. Gut 56:725-732
21. Glaudemans AW, Maccioni F, Mansi L, Dierckx RA, Signore A (2010) Imaging of cell trafficking in Crohn's disease. J Cell Physiol 223:562-571
22. Gotthardt M, Bleeker-Rovers CP, Boerman OC, Oyen WJ (2010) Imaging of inflammation by PET, conventional scintigraphy, and other imaging techniques. J Nucl Med Off Publ Soc Nucl Med 51:1937-1949
23. Neurath MF, Vehling D, Schunk K, et al. (2002) Noninvasive assessment of Crohn's disease activity: a comparison of 18F-fluorodeoxyglucose positron emission tomography, hydromagnetic resonance imaging, and granulocyte scintigraphy with labeled antibodies. Am J Gastroenterol 97:1978-1985
24. Lemberg DA, Issenman RM, Cawdron R, et al. (2005) Positron emission tomography in the investigation of pediatric inflammatory bowel disease. Inflamm Bowel Dis 11:733-738
25. Loffler M, Weckesser M, Franzius C, Schober O, Zimmer KP (2006) High diagnostic value of 18F-FDG-PET in pediatric patients with chronic inflammatory bowel disease. Ann N Y Acad Sci 1072:379-385
26. Meisner RS, Spier BJ, Einarsson S, et al. (2007) Pilot study using PET/CT as a novel, noninvasive assessment of disease activity in inflammatory bowel disease. Inflamm Bowel Dis 13:993-1000
27. Louis E, Ancion G, Colard A, et al. (2007) Noninvasive assessment of Crohn's disease intestinal lesions with (18)F-FDG PET/CT. J Nucl Med Off Publ Soc Nucl Med 48: 1053-1059
28. Dabritz J, Jasper N, Loeffler M, Weckesser M, Foell D (2011) Noninvasive assessment of pediatric inflammatory bowel disease with (1)F-fluorodeoxyglucose- positron emission tomography and computed tomography. Eur J Gastroenterol Hepatol 23:81-89
29. Shyn PB, Mortele KJ, Britz-Cunningham SH, et al. (2010) Lowdose 18F-FDG PET/CT enterography: improving on CT enterography assessment of patients with Crohn disease. J Nucl Med Off Publ Soc Nucl Med 51:1841-1848
30. Das CJ, Makharia G, Kumar R, et al. (2007) PET-CT enteroclysis: a new technique for evaluation of inflammatory diseases of the intestine. Eur J Nucl Med Mol Imag 34:2106-2114
31. Ahmadi A, Li Q, Muller K, et al. (2010) Diagnostic value of noninvasive combined fluorine-18 labeled fluoro-2-deoxy-d-glucose positron emission tomography and computed tomography enterography in active Crohn's disease. Inflamm Bowel Dis 16:974-981
32. Harvey RF, Bradshaw JM (1980) A simple index of Crohn's-disease activity. Lancet 1:514
33. Guyatt G, Mitchell A, Irvine EJ, et al. (1989) A new measure of health status for clinical trials in inflammatory bowel disease. Gastroenterology 96:804-810
34. Vermeire S, Van Assche G, Rutgeerts P (2004) C-reactive protein as a marker for inflammatory bowel disease. Inflamm Bowel Dis 10:661-665
35. Yanai H, Hanauer SB (2011) Assessing response and loss of response to biological therapies in IBD. Am J Gastroenterol 106:685-698
36. Pellegrino D, Bonab AA, Dragotakes SC, et al. (2005) Inflammation and infection: imaging properties of 18F-FDG-labeled white blood cells versus 18F-FDG. J Nucl Med Off Publ Soc Nucl Med 46:1522-1530
37. Spier BJ, Perlman SB, Jaskowiak CJ, Reichelderfer M (2010) PET/CT in the evaluation of inflammatory bowel disease: studies in patients before and after treatment. Mol Imag Biol Off Publ Acad Mol Imag 12:85-88
38. Weber WA (2009) Assessing tumor response to therapy. J Nucl Med Off Publ Soc Nucl Med 50(Suppl 1):1S-10S
39. Contractor KB, Aboagye EO (2009) Monitoring predominantly cytostatic treatment response with 18F-FDG PET. J Nucl Med Off Publ Soc Nucl Med 50(Suppl 1):97S-105S
40. Elzinga EH, van der Laken CJ, Comans EF, et al. (2011) 18F-FDG PET as a tool to predict the clinical outcome of infliximab treatment of rheumatoid arthritis: an explorative study. J Nucl Med Off Publ Soc Nucl Med 52:77-80
41. Van Assche G, Geboes K, Rutgeerts P (2004) Medical therapy for Crohn's disease strictures. Inflamm Bowel Dis 10:55-60
42. Jacene HA, Ginsburg P, Kwon J, et al. (2009) Prediction of the need for surgical intervention in obstructive Crohn's disease by 18F-FDG PET/CT. J Nucl Med Off Publ Soc Nucl Med 50:1751-1759
43. Sahni VA, Shyn PB (2010) Predicting the need for surgery in obstructive Crohn's disease: how hot is PET/CT? Inflamm Bowel Dis 16:2182-2183
44. Burke JP, Mulsow JJ, O'Keane C, et al. (2007) Fibrogenesis in Crohn's disease. Am J Gastroenterol 102:439-448
45. Borley NR, Mortensen NJ, Kettlewell MG, et al. (2001) Connective tissue changes in ileal Crohn's disease: relationship to disease phenotype and ulcer-associated cell lineage. Dis Colon Rectum 44:388-396
46. Mettler FA Jr, Huda W, Yoshizumi TT, Mahesh M (2008) Effective doses in radiology and diagnostic nuclear medicine: a catalog. Radiology 248:254-263
47. Coakley FV, Gould R, Yeh BM, Arenson RL (2011) CT radiation dose: what can you do right now in your practice? AJR Am J Roentgenol 196:619-625
48. Flicek KT, Hara AK, Silva AC, et al. (2010) Reducing the radiation dose for CT colonography using adaptive statistical iterative reconstruction: a pilot study. AJR Am J Roentgenol 195:126-131
49. Yau YY, Chan WS, Tam YM, et al. (2005) Application of intravenous contrast in PET/CT: does it really introduce significant attenuation correction error? J Nucl Med Off Publ Soc Nucl Med 46:283-291
50. Rubin DT, Surma BL, Gavzy SJ, et al. (2009) Positron emission tomography (PET) used to image subclinical inflammation associated with ulcerative colitis (UC) in remission. Inflamm Bowel Dis 15:750-755